Pfizer asks FDA to approve omicron COVID-19 booster shots for 5- to 11-year-olds
Pfizer asked U.S. regulators Monday to expand the use of its updated COVID-19 booster shot to children ages 5 to 11.
Elementary school-aged children already received kid-sized doses of Pfizer’s original vaccine, a third of the dose given to everyone 12 and older -- two primary shots plus a booster.
If the Food and Drug Administration agrees, they would start getting a kid-sized dose of the new omicron-targeted formula when it is time for their booster.
FDA vaccine chief Dr. Peter Marks said last week he expected a decision on boosters for that age group soon.
Pfizer and its partner BioNTech also announced a new study of the omicron-focused booster in even younger children, those ages 6 months through 4 years, to test different doses.
Updated boosters made by both Pfizer and rival Moderna rolled out earlier this month for everyone 12 and older. They’re a tweak to vaccines that already have saved millions of lives -- a combination or "bivalent" shot that contains half the original recipe and half protection against the BA.4 and BA.5 omicron relatives responsible for most of today’s COVID-19 cases.
The hope is that the modified boosters will help tamp down continuing COVID-19 cases and blunt another winter surge. As of last week, the Centers for Disease Control and Prevention said 4.4 million Americans had gotten an updated booster so far.
RELATED: Should I get the new COVID booster and flu shot at the same time? Your questions, answered